293 related articles for article (PubMed ID: 35179584)
1. Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.
Li Y; Xu S
JAMA Netw Open; 2022 Feb; 5(2):e220045. PubMed ID: 35179584
[TBL] [Abstract][Full Text] [Related]
2. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
Conti RM; Nikpay SS; Buntin MB
JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
[TBL] [Abstract][Full Text] [Related]
3. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
4. Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs.
Chang J; Karaca-Mandic P; Nikpay S; Jeffery MM
JAMA Health Forum; 2023 Jun; 4(6):e231485. PubMed ID: 37351874
[TBL] [Abstract][Full Text] [Related]
5. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
6. Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare.
Jung J; Xu WY; Kalidindi Y
Health Serv Res; 2018 Oct; 53(5):3528-3548. PubMed ID: 29355925
[TBL] [Abstract][Full Text] [Related]
7. The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B.
Han D
J Health Econ; 2023 May; 89():102754. PubMed ID: 37030057
[TBL] [Abstract][Full Text] [Related]
8. Medicare Part B Spending on Macular Degeneration Treatments Associated With Manufacturer Payments to Ophthalmologists.
Dickson SR; James KE
JAMA Health Forum; 2023 Sep; 4(9):e232951. PubMed ID: 37682553
[TBL] [Abstract][Full Text] [Related]
9. Relationship between initiation of 340B participation and hospital safety-net engagement.
Nikpay SS; Buntin MB; Conti RM
Health Serv Res; 2020 Apr; 55(2):157-169. PubMed ID: 32187392
[TBL] [Abstract][Full Text] [Related]
10. Association Between a Bundled Payment Program for Lower Extremity Joint Replacement and Patient Outcomes Among Medicare Advantage Beneficiaries.
Sutherland A; Boudreau E; Bowe A; Huang Q; Liao JM; Flagg M; Cousins D; Antol DD; Shrank WH; Powers BW; Navathe AS
JAMA Health Forum; 2023 Jun; 4(6):e231495. PubMed ID: 37355996
[TBL] [Abstract][Full Text] [Related]
11. The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program.
Bond AM; Dean EB; Desai SM
Health Aff (Millwood); 2023 May; 42(5):632-641. PubMed ID: 37126754
[TBL] [Abstract][Full Text] [Related]
12. A comparison of medication access services at 340B and non-340B hospitals.
Rana I; von Oehsen W; Nabulsi NA; Sharp LK; Donnelly AJ; Shah SD; Stubbings J; Durley SF
Res Social Adm Pharm; 2021 Nov; 17(11):1887-1892. PubMed ID: 33846100
[TBL] [Abstract][Full Text] [Related]
13. Consequences of the 340B Drug Pricing Program.
Desai S; McWilliams JM
N Engl J Med; 2018 Feb; 378(6):539-548. PubMed ID: 29365282
[TBL] [Abstract][Full Text] [Related]
14. A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?
San-Juan-Rodriguez A; Gellad WF; Shrank WH; Good CB; Hernandez I
J Manag Care Spec Pharm; 2021 May; 27(5):565-573. PubMed ID: 33908276
[No Abstract] [Full Text] [Related]
15. US Hospital Service Availability and New 340B Program Participation.
Owsley KM; Hasnain-Wynia R; Rooks RN; Tung GJ; Mays GP; Lindrooth RC
JAMA Health Forum; 2024 May; 5(5):e240833. PubMed ID: 38700853
[TBL] [Abstract][Full Text] [Related]
16. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019.
Dusetzina SB; Huskamp HA; Qin X; Keating NL
JAMA; 2022 Oct; 328(15):1515-1522. PubMed ID: 36255428
[TBL] [Abstract][Full Text] [Related]
17. Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
Mulligan K; Romley JA; Myerson R
BMC Res Notes; 2021 Jun; 14(1):228. PubMed ID: 34082835
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Spending Differences Between Beneficiaries in Medicare Advantage and the Medicare Shared Savings Program.
Parikh RB; Emanuel EJ; Brensinger CM; Boyle CW; Price-Haywood EG; Burton JH; Heltz SB; Navathe AS
JAMA Netw Open; 2022 Aug; 5(8):e2228529. PubMed ID: 35997977
[TBL] [Abstract][Full Text] [Related]
20. Medicare Beneficiaries' Perspectives on the Quality of Hospital Care and Their Implications for Value-Based Payment.
Trenaman L; Harrison M; Hoch JS
JAMA Netw Open; 2023 Jun; 6(6):e2319047. PubMed ID: 37342041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
